Document is current
Any future updates will be listed below
-
Authors
Tsuchiyagaito, Aki https://orcid.org/0000-0002-7606-1745
Kuplicki, Rayus https://orcid.org/0000-0003-2954-6421
Misaki, Masaya https://orcid.org/0000-0002-6829-4311
Edwards, Landon
Camprodon, Joan A. https://orcid.org/0000-0003-1282-9257
Fitzgerald, Kate https://orcid.org/0000-0002-6502-7031
Khalsa, Sahib S. https://orcid.org/0000-0003-2124-8585
Philip, Noah S. https://orcid.org/0000-0002-4889-8775
Paulus, Martin P. https://orcid.org/0000-0002-0825-3606
Guinjoan, Salvador M. https://orcid.org/0000-0002-1958-4259
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH127225, R33MH121641, R61MH129544, U01MH123427, R21MH138911, R01MH137331)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (P20GM121312)
- License Information
-
More Information
Article History
Received: 21 August 2025
Revised: 4 September 2025
Accepted: 15 September 2025
First Online: 25 September 2025
Competing interests
: MPP is an advisor to Spring Care, Inc., a behavioral health startup, he has received royalties for an article about methamphetamine in UpToDate. In the past three years, NSP is on the scientific advisory board to Pulvinar Neuro and Gray Matter Neurosciences, consultant to Motif Neurotech and reports royalties from UpToDate, all unrelated to the current work. KDF is an associate editor for Neuropsychopharmacology. The other authors report no biomedical financial interests or potential conflicts of interest.
